Clinical leadership Elucid is a Boston-based medical technology company focused on histology-validated software to inform precision cardiovascular treatment decisions, presenting a compelling case for expanding into hospitals and academic medical centers with cardiology and radiology departments.

AI powered growth Recent announcements around deep learning AI models for estimating FFR-CT andLesion Inspection Tool for Plaque-IQ indicate a strong emphasis on AI-driven plaque analysis, providing ample opportunity to upsell to hospitals adopting or expanding AI workflows in imaging.

Recognition & credibility Awards and board-level appointments, including MedTech Breakthrough Award for Best New Cardiology Technology Solution and on-boarding of notable directors, bolster credibility for enterprise deals and faster procurement cycles in risk-averse health systems.

Market traction Revenue is in the mid single-digit tens of millions with substantial funding, suggesting readiness for expansion into additional healthcare networks, partner integrations, and potential channel partnerships to scale adoption of Plaque-IQ and FFR-CT solutions.

Strategic fit opportunities The platform uniquely quantifies plaque characteristics non-invasively and aligns with value-based care by aiming to improve outcomes and reduce costs, making Elucid an attractive partner for health systems pursuing cardiovascular care optimization and cost containment.